Skip Navigation LinksHome > April 2011 - Volume 18 - Issue 4 > Future developments in the medical treatment of abnormal ute...
Text sizing:
doi: 10.1097/gme.0b013e3182127b53
Special Section: Causality, Diagnosis & Management of Abnormal Uterine Bleeding

Future developments in the medical treatment of abnormal uterine bleeding: what can we expect?

Simon, James A. MD, CCD, NCMP, FACOG

Collapse Box


New therapies for abnormal uterine bleeding have been slow to reach the marketplace for a variety of reasons. These reasons include the availability of cost-effective therapies already available and the extraordinarily difficult and expensive regulatory barriers emphasizing long-term safety. Common comorbidities like bleeding diatheses, adenomyosis, and leiomyomata further complicate clinical development, necessitating large study samples and making it more expensive. Even the accurate measurement of menstrual blood loss adds an additional hindrance to novel drug development. These obstacles and the currently available therapies will be reviewed in the context of developing new methods for approaching this complicated and prevalent clinical problem.

©2011The North American Menopause Society


Article Tools


Article Level Metrics

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.